-
公开(公告)号:US5190951A
公开(公告)日:1993-03-02
申请号:US773432
申请日:1991-10-09
申请人: Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
发明人: Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
IPC分类号: C07D219/06 , C07D221/16 , C07D401/06 , C07D471/04
CPC分类号: C07D401/06 , C07D219/06 , C07D221/16 , C07D471/04
摘要: Quinoline derivatives of the formula, ##STR1## wherein > A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group, R.sup.2 is a hydrogen atom, a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, a phenyl group which may have a substituent, a phenoxy group, an alkanoyloxy group, or an amino group which may have a substituent, R.sup.3 is a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group, and m is an integer of 1-3. The compounds and their salts exhibit a superior antiacetylcholinesterase activity with no side effects and are effective for the prevention or cure of senile dementia or memory disturbance.
-
公开(公告)号:US5300517A
公开(公告)日:1994-04-05
申请号:US53202
申请日:1993-04-28
申请人: Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
发明人: Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
IPC分类号: C07D219/06 , C07D221/16 , C07D401/06 , C07D471/04 , A61K31/445 , C07D401/04
CPC分类号: C07D401/06 , C07D219/06 , C07D221/16 , C07D471/04
摘要: Piperidine compounds of formula II: ##STR1## that exhibit anticholinesterase activity and are effective in treating dementia.
摘要翻译: 具有抗胆碱酯酶活性并有效治疗痴呆的式II的哌啶化合物:IMAGE(II)。
-
公开(公告)号:US5240934A
公开(公告)日:1993-08-31
申请号:US946620
申请日:1992-09-18
申请人: Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
发明人: Hiroshi Hasegawa , Kazuo Isomae , Takeshi Kotsugai , Noriaki Shioiri , Kumiko Sekine , Naokata Taido , Susumu Sato , Tadayuki Kuraishi
IPC分类号: C07D219/06 , C07D221/16 , C07D401/06 , C07D471/04
CPC分类号: C07D401/06 , C07D219/06 , C07D221/16 , C07D471/04
摘要: Quinoline derivatives of the formula, ##STR1## wherein >A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group, R.sup.2 is a hydrogen atom, a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, a phenyl group which may have a substituent, a phenoxy group, an alkanoyloxy group, or an amino group which may have a substituent, R.sup.3 is a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group, and m is an integer of 1-3. The compounds and their salts exhibit a superior anti-acetylcholinesterase activity with no side effects and are effective for the prevention or cure of senile dementia or memory disturbance.
摘要翻译: 其中> A表示基团> N-(CH 2)n - ,> C = C = CH(CH 2)n - 或> CH(CH 2)n - ,其中n为 0-7的整数; Y表示C = O或> CHOH基团,R1表示氢原子,卤素原子,烷基,烷氧基或烷硫基,R2表示氢原子,卤原子,烷基, 羟基,烷氧基,可以具有取代基的苯基,苯氧基,烷酰氧基或可以具有取代基的氨基,R3是氢原子,卤素原子,烷基或 烷氧基,m为1-3的整数。 化合物及其盐具有优异的抗乙酰胆碱酯酶活性,无副作用,对预防或治愈老年痴呆或记忆障碍有效。
-
公开(公告)号:US20140158611A1
公开(公告)日:2014-06-12
申请号:US14233239
申请日:2012-06-20
申请人: Junya Satoh , Kumiko Sekine
发明人: Junya Satoh , Kumiko Sekine
CPC分类号: A61M1/16 , B01D65/022 , B01D67/0088 , B01D69/02 , B01D69/08 , B01D71/38 , B01D71/44 , B01D71/48 , B01D71/58 , B01D71/68 , B01D2323/12 , B01D2325/28 , B01D2325/30
摘要: (Problem to be Solved)To obtain a hollow-fiber membrane blood purification device having excellent blood compatibility and antioxidative performance and highly stable antioxidative performance under severe environments.(Solution)A hollow-fiber membrane blood purification device provided with a hollow-fiber membrane containing a polysulfone-based resin, a polyvinyl pyrrolidone, a fat-soluble vitamin and a polymer having an ester group, in which an abundance of the fat-soluble vitamin on all surfaces of the hollow-fiber membrane is 2 mg or more and 18 mg or less based on 1 g of the hollow-fiber membrane, when the hollow-fiber membrane is extracted with ethanol, an extract is dried and subjected to measurement of an infrared absorption spectrum (IR), a ratio of absorbance (Abs(A)) of peak A in a vicinity of 1720 to 1730 cm−1 to absorbance (Abs(B)) of peak B in a vicinity of 1660 to 1670 cm−1, (Abs(A)/Abs(B)), is 0.01 or more and 0.3 or less, and a moisture content of the hollow-fiber membrane is 0 mass % or more and 600 mass % or less.
摘要翻译: (待解决的问题)获得在恶劣环境下具有优异的血液相容性和抗氧化性能以及高度稳定的抗氧化性能的中空纤维膜血液净化装置。 (溶液)具有含有聚砜系树脂,聚乙烯吡咯烷酮,脂溶性维生素和具有酯基的聚合物的中空纤维膜的中空纤维膜血液净化装置,其中, 当中空纤维膜用乙醇萃取时,中空纤维膜的所有表面上的可溶性维生素在1克中空纤维膜上为2mg以上至18mg以下,提取物干燥, 红外吸收光谱(IR)的测定,峰值A在1720〜1730cm -1附近的吸光度(Abs(A))与吸光度(Abs(B))的吸光度(Abs(B))在1660〜 1670cm -1,(Abs(A)/ Abs(B))为0.01以上且0.3以下,中空纤维膜的水分含量为0质量%以上至600质量%以下。
-
-
-